Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd.

0.05
EUR
0.00
(0.00%)
-0.01EPS
10.56MMarket Cap

Total Valuation

EUR

As of December 31, 2025, Ventripoint Diagnostics Ltd. carries a market capitalization of 10.56M, placing it among publicly traded companies globally. Its enterprise value stands at 12.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.56M
Enterprise Value12.14M

Share Statistics

As of December 31, 2025, Ventripoint Diagnostics Ltd. has 169.22M shares outstanding.

Shares Outstanding169.22M

Valuation Ratios

These figures are as of December 31, 2025. The price-to-sales ratio is 92.62, and the price-to-book ratio stands at -4.13.

PS Ratio92.62
PB Ratio-4.13
P/TBV Ratio-4.13
P/FCF Ratio-10.72
P/OCF Ratio-10.72

Enterprise Valuation

These figures are as of December 31, 2025. The EV/Sales ratio of 108.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.14M versus a market cap of 10.56M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales108.79

Financial Position

As of December 31, 2025, Ventripoint Diagnostics Ltd. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -63.44, indicating conservative leverage, while an interest coverage ratio of -6.35 demonstrates limited ability to service its debt obligations.

Current Ratio0.08
Quick Ratio0.04
Debt / Equity-63.44
Debt / EBITDA-0.78
Interest Coverage-6.35

Financial Efficiency

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -566.36, reflecting losses generated across the asset base.

Return on Assets (ROA)-566.36

Stock Price Statistics

EUR

As of the close on November 17, 2026, Ventripoint Diagnostics Ltd.'s stock has declined approximately 2.94% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.07.

52-Week Price Change-2.94%
50-Day Moving Average0.06
200-Day Moving Average0.07

Income Statement

EUR

Over the twelve months ended December 31, 2025, Ventripoint Diagnostics Ltd. generated 111,615.69 in revenue and converted that into -1.99M in net income, yielding earnings per share of -0.01. EBITDA reached -2.07M, while operating income came in at -2.11M.

Revenue111,615.69
Operating Income-2.11M
Pretax Income-2.02M
Net Income-1.99M
EBITDA-2.07M
EBIT-2.11M
Earnings Per Share (EPS)-0.01

Balance Sheet

EUR

As of December 31, 2025, Ventripoint Diagnostics Ltd. holds 34,359.75 in cash and equivalents against 1.62M in total debt, resulting in a net debt position of 1.49M. Total book value stands at -2.55M, with working capital of -2.56M providing operational flexibility.

Cash & Cash Equivalents34,359.75
Total Debt1.62M
Net Debt1.49M
Equity (Book Value)-2.55M
Book Value Per Share-0.02
Working Capital-2.56M

Cash Flow

EUR

Ventripoint Diagnostics Ltd. produced -964,571.11 in operating cash flow over the twelve months ended December 31, 2025.

Operating Cash Flow-964,571.11
Free Cash Flow-964,571.11
FCF Per Share-0.01

Margins

These figures cover the twelve months ended December 31, 2025. The operating margin of -1,889.37 and net profit margin of -1,778.62 provide insight into operational efficiency.

Operating Margin-1,889.37
Pretax Margin-1,807.64
Profit Margin-1,778.62
EBITDA Margin-1,855.33

Dividends & Yields

Over the twelve months ended December 31, 2025, Ventripoint Diagnostics Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -9.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.01, meaning Ventripoint Diagnostics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-9.01
FCF Yield-9.33

Stock Splits

Ventripoint Diagnostics Ltd.'s most recent stock split took place on December 7, 2015 with a 10:1 split ratio.

Last Split Date12/7/2015
Split Ratio10:1

Scores

As of December 31, 2025, Ventripoint Diagnostics Ltd. has an Altman Z-Score of -214.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-214.36